Paola Queirolo

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

Paolo A. Ascierto, Dirk Schadendorf, Carola Berking et al. · The Lancet Oncology · 2013 · 638 citations

Tumor Biology, Open-label Phase 2, Medicine +12

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

Steven O’Day, Michele Maio, Vanna Chiarion‐Sileni et al. · Annals of Oncology · 2010 · 510 citations

Pretreated Advanced Melanoma, Medicine, Melanoma +7

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà et al. · The Lancet Oncology · 2020 · 505 citations

Checkmate 238, Surgical Oncology, Medicine +11

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto et al. · The Lancet Oncology · 2017 · 482 citations · Full text

Oncology, Binimetinib Versus Dacarbazine, Medicine +7